Vivus (NASDAQ:VVUS) Rating Lowered to Strong Sell at ValuEngine

Vivus (NASDAQ:VVUS) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Monday, April 2nd.

Separately, Zacks Investment Research downgraded shares of Vivus from a “buy” rating to a “hold” rating in a report on Saturday, January 6th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ VVUS traded down $0.01 during mid-day trading on Monday, hitting $0.40. The company’s stock had a trading volume of 242,871 shares, compared to its average volume of 615,822. The firm has a market capitalization of $44.85, a PE ratio of -1.38 and a beta of 0.62. The company has a current ratio of 6.80, a quick ratio of 6.34 and a debt-to-equity ratio of -24.71. Vivus has a one year low of $0.33 and a one year high of $1.38.



Vivus (NASDAQ:VVUS) last released its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. Vivus had a negative net margin of 46.67% and a negative return on equity of 843.43%. The business had revenue of $11.94 million for the quarter. equities research analysts anticipate that Vivus will post -0.45 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of VVUS. Northern Trust Corp raised its holdings in shares of Vivus by 16.8% in the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 39,473 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Vivus by 166.2% in the third quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 246,927 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in shares of Vivus in the third quarter valued at approximately $192,000. OxFORD Asset Management LLP grew its stake in shares of Vivus by 14.0% in the third quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock valued at $1,040,000 after buying an additional 129,871 shares in the last quarter. Finally, Creative Planning grew its stake in shares of Vivus by 1,691.3% in the fourth quarter. Creative Planning now owns 366,706 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 346,235 shares in the last quarter. Institutional investors own 24.82% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Vivus (NASDAQ:VVUS) Rating Lowered to Strong Sell at ValuEngine” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://stocknewstimes.com/2018/04/17/vivus-vvus-rating-lowered-to-strong-sell-at-valuengine.html.

Vivus Company Profile

VIVUS, Inc, a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vivus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply